

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

#### STA Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

#### Draft guidance consultation

(when draft guidance previously issued)

- |                                |   |
|--------------------------------|---|
| 1.                             | Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these? |
| No equality issues identified. |   |

- |                                |   |
|--------------------------------|---|
| 2.                             | Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group? |
| No equality issues identified. |   |

- |                                |  |
|--------------------------------|--|
| 3.                             | Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability? |
| No equality issues identified. |  |

4.	Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?
No.	

5.	Have the committee's considerations of equality issues been described in the draft guidance, and, if so, where?
Section 3.16 of the draft guidance.	

**Approved by Associate Director (name):** Ross Dent

**Date:** 15/01/2026